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CHRONIC KIDNEY DISEASE AND CARDIO-
VASCULAR DISEASES
The number of individuals with chronic kidney
disease (CKD) has dramatically increased in Japan
as well as across the world. Patients with CKD, par-
ticularly those with end-stage renal disease (ESRD)
on maintenance dialysis, have a high risk of cardio-
vascular disease (CVD) (1). CVD accounts for over
50% of annual mortality in individuals on hemodialy-
sis (2). It is understood that both atherosclerosis
and arteriosclerosis go hand-in-hand with vascular
calcification, which is frequently observed in ESRD
patients (3-5). Endothelial dysfunction, which is gen-
erally implicated in hyperglycemia, hyperlipidemia
and hypertension, is a major pathomechanism in
the process of atherosclerosis in both ESRD patients
and non-CKD patients (6).
Diabetes mellitus (DM) is the leading cause of
ESRD in Japan and the Western world. In Japan,
about 40% of new hemodialysis patients (about 10,000
peoples per year) are diagnosed as having ESRD with
DM (7). Hyperglycemia is also an important risk
factor for CVD (8). The mechanism underlying the
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progression to CVD in ESRD patients with DM is
very complicated, but chronic hyperglycemia and
advanced glycation end products increase oxidative
stress in the endothelial cells, resulting in lower NO
availability, DNA damage and lipid oxidation, and
eventually cause endothelial dysfunction (9). Im-
provement of hyperglycemia can slow the micro-
and macro-vasculopathy that may play a central role
in the development of CVD (10, 11).
Recent reports have demonstrated that the pres-
ence of vascular calcification is closely correlated
not only with CVD but also with all-cause mortality
(4, 12). Intimal calcification of the atherosclerotic
plaques and medial calcification of both large and
small arteries are frequently observed in ESRD pa-
tients (13). Both types of vascular calcification are
associated with cardiovascular mortality (14). Jono,
et al. have demonstrated that hyperphosphatemia
and increased CaP not only accelerate intimal cal-
cification, but also stimulate the differentiation of vas-
cular smooth muscle cells to osteoblastic cells, re-
sulting in medial calcification (15). Thus, hyperphos-
phatemia is also a risk factor for CVD in ESRD pa-
tients (16, 17).
From these observations, control of hyperglyce-
mia and hyperphosphatemia might be important way
to prevent CVD in ESRD patients with DM. Cur-
rently, many drugs are available for controlling hy-
perglycemia and hyperphosphatemia. However, nu-
tritional treatment occupies a critical role in reduc-
ing CVD risk and preventing progressive damage
to the kidneys and cardiovascular system.
CONTROL OF POSTPRANDIAL HYPER-
GLYCEMIA BY PALATINOSE-BASED FUNC-
TIONAL FOOD
Palatinose (isomaltulose) has been shown to be
an insulin-sparing caloric sweetener with a lower
glycemic index than that of either sucrose or a non-
cariogenic caloric sweetener (18, 19). This difference
may be due to variation in digestibility because the
hydrolysis of palatinose by homogenates of human
intestinal mucosa is one-quarter of that of sucrose
(20). However, palatinose is completely cleaved and
absorbed (21). We previously designed a novel en-
teral liquid formula, Inslow (MHN-01), by replac-
ing dextrin in the standard balanced formula (SBF)
with palatinose at 55.7% of the carbohydrate content
(Table 1) (22).
The effects of Inslow on carbohydrate metabo-
lism in Sprague-Dawley rats have been compared
with those of SBF (22). After a bolus ingestion of
each formula, the peak levels of plasma glucose (PG)
in the femoral vein of the Inslow group were found
to be significantly smaller than those of the SBF
group (Fig. 1). Thus, because postprandial hyper-
glycemia leads to increased oxidative stress in blood
vessels and other organs, Inslow is likely to be
beneficial for controlling the progression of both
DM and CVD.
Table 1 Composition of Inslow and standard balanced for-
mula (SBF).
Inslow SBF
Energy 1 kcal/ml 1 kcal/ml
Protein 20.0 % 16.0 %
Fat 29.7 % 25.0 %
Saturated fatty acid 10.9 % 9.0 %
Monounsaturated fatty acid 72.3 % 45.0 %
Polyunsaturated fatty acid 15.1 % 40.0 %
Carbohydrate 50.3 % 59.0 %
Branched dextrin 23.9 % 0 %
Dextrin 0 % 97.2 %
Sucrose 0 % 2.8 %
Xylitol 5.3 % 0 %
Palatinose 55.7 % 0 %
Other carbohydrate* 15.1 % 0 %
*Other carbohydrate : mixed carbohydrate from raw material
and dietary fiber
Fig. 1 Changes in plasma glucose in the femoral vein after
oral administration of Inslow (MHN-01) (open circle), stan-
dard balanced formula (SBF) (closed square), or glucose (open
triangle) in Sprague-Dawley rats. The rats received 7.16 mL/kg
BW of Inslow (energy 30.0 KJ/kg, carbohydrates 0.90 g/kg
BW, fat 0.24 g/kg, protein 0.36 g/kg), 6.11 mL/kg BW of SBF
(energy 25.6 KJ/kg, carbohydrates 0.90 g/kg, fat 0.17 g/kg,
protein 0.24 g/kg), and 6 mL/kg BW of 15% D-glucose solution
(energy 15.1 KJ/kg, carbohydrates 0.90 g/kg). Data are mean
SEM #P0.05 vs MHN-01, *P0.01 vs MHN-01.
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CONTROL OF HYPERPHOSPHATEMIA IN
ESRD PATIENTS BY A LOW PHOSPHATE
DIET
Dietary control of hyperphosphatemia is another
important way in which to prevent CVD in ESRD
patients. Ganesh, et al. demonstrated that ESRD pa-
tients with elevated serum phosphate (6.5mg/dL)
show high cardiovascular mortality, as compared
with those with low serum phosphate (6.5 mg/
dL), in a 2-year follow-up study of two large random
samples of patients on hemodialysis (n=12,833) in
the United States (23). Another study has also re-
ported that dialysis patients show increased risk of
mortality and secondary hyperparathyroidism when
their serum phosphorus levels exceed 6.5 mg/dL
(24). By contrast, serum Ca showed no correlation
with the relative risk of mortality in these studies (23,
24). These observations suggest that control of se-
rum phosphate levels below 6.5 mg/dL could be
needed to decrease the risk of CVD and mortality
in ESRD patients.
Control of dietary phosphorus intake is the most
effective way to manage hyperphosphatemia. In gen-
eral, the average daily consumption of phosphorus
in the Japanese population is approximately 1,200 mg.
Cupisti, et al. recommended that a dietary intake
of around 750-800 mg/day of phosphate can be
planned for a large percentage of patients, although
the acceptable amount of phosphate intake may vary
with the frequency of dialysis, type and dose of phos-
phate binders, and nutritional status (25). In the past
decades, several types of phosphate binder such as
sevelamer hydrochloride, calcium acetate and lan-
thanum carbonate, among others, have become avail-
able for the treatment of hyperphosphatemia in
hemodialysis patients (26) ; however, restriction of
dietary phosphorus intake is likely to be needed to
achieve optimal effects with these drugs. For dietary
protein and phosphate restriction in CKD and ESRD
patients, Renalen Pro has been widely used as an
enteral liquid formula in a low protein and low phos-
phate diet for the nutritional treatment of CKD and
ESRD patients.
As noted above, dietary control of both hypergly-
cemia and hyperphosphatemia should be consid-
ered to be the basic treatment in patients with dia-
betic nephropathy. Recently, Renalen LoGIC, in
which the carbohydrate content in Renalen Pro
has been partially replaced with palatinose, similar
to Inslow, has become available. Administration of
Renalen LoGIC in GK rats results in a lower peak
value of serum glucose as compared with Renalen
Pro (Fig. 2). Thus, Renalen LoGIC is designed for
use as a low phosphate and low glycemic index diet,
and can be useful for the prevention of postprandial
hyperglycemia as well as hyperphosphatemia. The
beneficial effects of Renalen LoGIC are likely to
be helpful in the treatment of diabetic nephropathy
to decrease the risk of CVD.
HYPERPHOSPHATEMIA IS NOT ONLY A
PROBLEM IN ESRD PATIENTS
Hyperphosphatemia is not a problem limited to
ESRD patients. Tonelli, et al. reported a graded in-
dependent relation between higher levels of serum
phosphate and risk of death or cardiovascular events
in people with prior myocardial infarction, most of
whom had serum phosphate levels within the nor-
mal range (27). In addition, Nishida, et al. demon-
strated that after ingestion of a meal containing
400 mg of phosphate and 200 mg of calcium, desig-
nated as the average mineral consumption in Japan,
serum Pi levels increased at 2 h and were sustained
until 6 h after the meal in eight healthy young males
(28). Furthermore, a meal containing 1200 mg of
phosphate and 200 mg of calcium increased serum
Pi levels at 2 h after ingestion (Fig. 3). The peak
values exceeded the normal range (between 2.5 and
4.5 mg/dL) in seven of the eight subjects. These
results suggest that over-intake of phosphorus from
diet can cause postprandial hyperphosphatemia, even
Fig. 2 Changes in serum phosphate levels in the femoral
vein after oral administration of meals with different amounts
of phosphate in humans. P400 (closed circle) contained 200 mg
of calcium and 400 mg of phosphate, P800 (open triangle) con-
tained 200 mg of calcium and 800 mg of phosphate, and P1200
(open square) contained 200 mg of calcium and 1,200 mg of phos-
phate. Data are meanSEM for eight subjects. *P0.05 vs P400,
P0.05 vs P800.
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if the fasting serum phosphate level is in the nor-
mal range. We note that postprandial hyperphos-
phatemia might be a risk factor for CVD and mor-
tality even in individuals without ESRD.
ADVANTAGE OF A LOW GLYCEMIC IN-
DEX AND LOW PHOSPHATE DIET ON
AGING-RELATED DISEASES-LESSONS
FROM KNOCKOUT MICE
The mechanism underlying the association be-
tween serum phosphate levels and adverse clinical
outcomes has not been clarified as yet. However,
two experimental animals have provided us with in-
teresting information : one is fibroblast growth fac-
tor 23 (FGF-23) knockout mice (Fgf23 -/-) (29), the
other is klotho mutant mice (30). FGF 23 is a re-
cently identified phosphaturic factor that is produced
in bone and is a potent inhibitor of renal phosphate
reabsorption activity (31, 32). Klotho has been iden-
tified as an anti-aging factor (29). klotho mutant mice,
in which klotho gene expression is dramatically de-
creased by a mutation in the promoter region, show
a premature aging-like phenotype and short lifespan
(33, 34). Both Fgf23 -/- and klotho mice exhibit short
lifespan and various premature aging-like characteris-
tics, such as arteriosclerosis, ectopic calcification in
various soft tissues, osteopenia, emphysema, atrophy
of the skin, and severe hyperphosphatemia with in-
creased concentration of serum 1,25-dihydroxyvitamin
D3 (1,25-(OH)2D3). Surprisingly, depletion of die-
tary vitamin D intake can ameliorate the most of the
phenotypic characteristics of these mice including
hyperphosphatemia (34, 35). Furthermore, a vitamin-
D-deficient diet decreased blood glucose and insu-
lin concentrations in klotho -deficient mice (34). There-
fore, Klotho protein plays a key role in the control
of mineral and vitamin D metabolism.
How can klotho work as a regulator of vitamin D
and mineral metabolism Most recent reports have
demonstrated that Klotho protein is necessary for
binding of FGF23 to the FGF receptors (36, 37).
The resulting signaling complex regulates both 1 α-
hydroxylase, which is a rate-limiting enzyme in
the production of 1,25-(OH)2D3, and the sodium-
dependent phosphate transporters (NaPi-IIa and
NaPi-IIc), which mediate the rate-limiting step in
renal phosphate reabsorption (38). Thus, impairment
of FGF23/Klotho signaling in klotho knockout mice
and Fgf23 knock out mice may cause disregulation
of mineral metabolism, leading to the premature
aging-like phenotype observed (39, 40).
One possible pathomechanism may be oxidative
stress. Yamamoto, et al. have demonstrated that
Klotho-induced inhibition of insulin/IGF-1 signal-
ing is associated with increased resistance to oxi-
dative stress (41). In addition, Morishita, et al. have
reported that phosphate restriction can increase the
expression of Klotho protein in normal and klotho
mutant mice (36). Recently, we reported that an ele-
vation of extracellular phosphate increased the pro-
duction of reactive oxygen species in bovine aortic
endothelial cells (42), suggesting that hyperphos-
phatemia may be involved in endothelial dysfunc-
tion and insulin resistance resulting from oxidative
stress. Thus, impairment of the counter-regulation
between phosphate metabolism and FGF23/Klotho
signaling may play a part in various aging-related dis-
eases and short lifespan. Controlling phosphate and
vitamin D intake, coupled with a low glycemic index
diet, may thus provide an advantage in both the pre-
vention of aging-related diseases and increasing
lifespan by reducing oxidative stress and other ad-
verse effects.
Fig. 3 Changes in plasma glucose levels
in the femoral vein after oral administration
of Renalen Pro 1.0 (closed circle) or
Renalen LoGIC (open circle) in GK rats.
The rats received 12 kcal/kg of Renalen
Pro1.0 or Renalen LoGIC1.0 orally. Data
are meanSEM for five rats. *P0.05 vs
Renalen Pro 1.0
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CONCLUSION
A low glycemic index and low phosphate diet
would be a useful treatment for CKD patients, es-
pecially those with DM, to reduce their risk of CVD
and mortality. In addition, this diet may be benefi-
cial in the prevention of several aging-related dis-
eases such as CVD even in healthy individuals. Fur-
ther studies are required to clarify the mechanism
underlying the association between phosphate and
adverse clinical outcomes in patients, and a large-
scale trial of the prevention of aging-related diseases
by phosphate restriction in the human population
is warranted.
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